Helix BioPharma Corp. (TSX:HBP)
Canada · Delayed Price · Currency is CAD 0.9000
0.00 (0.00%)
Nov 5, 2026, 2:41 PM EST
Helix BioPharma Balance Sheet
Financials in millions CAD. Fiscal year is August - July.
Millions CAD. Fiscal year is Aug - Jul.
Assets
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 31, 2026 | Jul '25 Jul 31, 2025 | Jul '24 Jul 31, 2024 | Jul '23 Jul 31, 2023 | Jul '22 Jul 31, 2022 |
Cash & Equivalents | 0.8 | 0.07 | 1.08 | 0.81 | 3.25 |
Cash & Short-Term Investments | 0.8 | 0.07 | 1.08 | 0.81 | 3.25 |
Cash Growth | 1136.92% | -93.99% | 33.79% | -75.15% | -8.78% |
Accounts Receivable | 0.03 | - | - | - | - |
Other Receivables | - | 0.12 | 0.05 | 0.06 | 0.28 |
Receivables | 0.03 | 0.12 | 0.05 | 0.06 | 0.28 |
Prepaid Expenses | 0.15 | 0.22 | 0.32 | 0.13 | 0.16 |
Total Current Assets | 0.99 | 0.41 | 1.46 | 1 | 3.7 |
Property, Plant & Equipment | - | 0 | 0.03 | 0.03 | 0.04 |
Other Intangible Assets | 18.39 | 18.39 | 0 | - | - |
Total Assets | 19.38 | 18.8 | 1.49 | 1.03 | 3.73 |
Liabilities
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 31, 2026 | Jul '25 Jul 31, 2025 | Jul '24 Jul 31, 2024 | Jul '23 Jul 31, 2023 | Jul '22 Jul 31, 2022 |
Accounts Payable | 1.01 | 2.3 | 0.86 | 0.49 | 0.6 |
Accrued Expenses | - | 0.58 | 0.72 | 0.38 | 0.35 |
Short-Term Debt | 4.16 | 0.34 | - | - | - |
Current Portion of Long-Term Debt | - | - | - | - | 2.47 |
Current Portion of Leases | - | 0 | - | - | - |
Other Current Liabilities | - | - | - | 1 | -0 |
Total Current Liabilities | 5.17 | 3.22 | 1.58 | 1.87 | 3.41 |
Other Long-Term Liabilities | - | - | - | - | 0 |
Total Liabilities | 5.17 | 3.22 | 1.58 | 1.87 | 3.41 |
Shareholders' Equity
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 31, 2026 | Jul '25 Jul 31, 2025 | Jul '24 Jul 31, 2024 | Jul '23 Jul 31, 2023 | Jul '22 Jul 31, 2022 |
Common Stock | 180.7 | 179.29 | 158.57 | 152.07 | 147.51 |
Additional Paid-In Capital | 49.51 | 48.3 | 47.36 | 44.14 | 37.59 |
Retained Earnings | -219.23 | -215.88 | -210.67 | -201.41 | -195.12 |
Comprehensive Income & Other | 3.23 | 3.87 | 4.65 | 4.36 | 10.34 |
Total Common Equity | 14.21 | 15.59 | -0.09 | -0.85 | 0.32 |
Shareholders' Equity | 14.21 | 15.59 | -0.09 | -0.85 | 0.32 |
Total Liabilities & Equity | 19.38 | 18.8 | 1.49 | 1.03 | 3.73 |
Additional Metrics
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 31, 2026 | Jul '25 Jul 31, 2025 | Jul '24 Jul 31, 2024 | Jul '23 Jul 31, 2023 | Jul '22 Jul 31, 2022 |
Total Debt | 4.16 | 0.34 | - | - | 2.47 |
Net Cash (Debt) | -3.35 | -0.27 | 1.08 | 0.81 | 0.78 |
Net Cash Growth | - | - | 33.79% | 3.06% | - |
Net Cash Per Share | -0.04 | -0.00 | 0.02 | 0.02 | 0.03 |
Filing Date Shares Outstanding | 76.38 | 76.38 | 49.02 | 43.33 | 34.86 |
Total Common Shares Outstanding | 76.38 | 74.16 | 49.02 | 40 | 34.36 |
Working Capital | -4.18 | -2.81 | -0.12 | -0.88 | 0.28 |
Book Value Per Share | 0.19 | 0.21 | -0.00 | -0.02 | 0.01 |
Tangible Book Value | -4.18 | -2.8 | -0.09 | -0.85 | 0.32 |
Tangible Book Value Per Share | -0.05 | -0.04 | -0.00 | -0.02 | 0.01 |
Machinery | - | 1.22 | 1.46 | 1.44 | 1.44 |
Leasehold Improvements | - | - | 0.36 | 0.36 | 0.36 |